1. FDA Public Meeting Report on 'Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications'
- Author
-
Diana L. Blithe, Vivek S. Purohit, Alison Edelman, Mohammad Ahsanul Akbar, Joachim Höchel, Erin Berry-Bibee, Ruth S. Day, Jim A. Turpin, Naomi K. Tepper, Myong-Jin Kim, David G. Strauss, Roxanne Jamshidi, Lei Zhang, Pamela E. Scott, Chongwoo Yu, Li Li, and Haiying Sun
- Subjects
Drug ,medicine.medical_specialty ,media_common.quotation_subject ,030226 pharmacology & pharmacy ,Food and drug administration ,03 medical and health sciences ,0302 clinical medicine ,Drug Development ,Agency (sociology) ,Contraceptive Agents, Female ,medicine ,Humans ,Drug Interactions ,Pharmacology (medical) ,030212 general & internal medicine ,media_common ,Panel discussion ,Pharmaceutical industry ,Pharmacology ,United States Food and Drug Administration ,business.industry ,Public health ,Drug interaction ,United States ,Drug development ,Family medicine ,Public Health ,business - Abstract
Potential drug interactions with hormonal contraceptives are an important public health concern. A public meeting on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implication" was hosted by the United States Food and Drug Administration (FDA). The meeting endeavored to provide an opportunity for the FDA to seek input from experts on the public health concerns associated with the use of hormonal contraceptives and interacting drugs that might affect efficacy and safety, including pharmacokinetic/pharmacodynamic considerations, in the design of drug interaction studies of hormonal contraceptives for drug development and approaches to translating the results of drug interaction information into informative labeling and communication. The input received could be used to refine FDA's thinking on hormonal contraceptives drug interaction study design and interpretation and labeling communication of drug interaction risk. This meeting benefited from strong and diverse participation from the Center for Drug Evaluation and Research at the FDA, Centers for Disease Control and Prevention, National Institutes of Health, Swedish Medical Products Agency, pharmaceutical industry, and representatives of academia. This report provides a summary of the key discussion based on the presentations and panel discussion.
- Published
- 2018
- Full Text
- View/download PDF